265 
0 Kommentare
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V.
(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief
Executive Officer of Merus, will present at Canaccord Genuity’s 44th Annual Growth Conference on Tuesday, August 13, 2024 from 9:00-9:25 a.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus
is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several
of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’
website, X and LinkedIn.
Multiclonics, Biclonics and Triclonics are registered trademarks of Merus N.V.
CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. Assoc. Director IR/Corp Comms 617-230-4165 k.farren@merus.nl
URL kopieren
Per E-Mail teilen
Artikel drucken